CD8A and non-small cell lung carcinoma: In addition, in the initial PD‐1 treatment, the differentiation state of peripheral CD8+ T cells partially regulates the expansion of TEEM to target antitumor immunity, thus regulating the response of PD‐1 targeted immunotherapy in advanced NSCLC.